These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8998823)

  • 1. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Opíchalová D; Farbiaková V
    Cas Lek Cesk; 2000 Jul; 139(13):401-6. PubMed ID: 10971970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma].
    Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V
    Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
    Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
    Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
    Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
    Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in multiple myeloma.
    Kyle RA
    Stem Cells; 1995 Aug; 13 Suppl 2():56-63. PubMed ID: 8520513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
    Wierzbowska A; Urbańska-Ryś H; Robak T
    Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
    Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
    Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
    Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on serum soluble interleukin-6 receptor levels in patients with malignant hematological diseases].
    Li D; Yang J; Cui W; Ma C; Ma C; Ji E; Li J; Li G; Ma C
    Zhonghua Xue Ye Xue Za Zhi; 1997 Nov; 18(11):577-80. PubMed ID: 15625895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
    Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus].
    Scudla V; Horák P; Faltýnek L; Pospísil Z; Budíková M; Hermanová Z
    Cas Lek Cesk; 1998 Jan; 137(2):44-7. PubMed ID: 9511265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 and soluble IL-6 receptor levels change differently after surgery both in the blood and in the operative field.
    Hisano S; Sakamoto K; Ishiko T; Kamohara H; Ogawa M
    Cytokine; 1997 Jun; 9(6):447-52. PubMed ID: 9199879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.